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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized clinically by progressive 
memory deficits, impaired cognitive function, and altered and inappropriate behavior. Aging 
represents the most important risk factor for AD and the global trend in the phenomenon of 
population aging has dramatic consequences for public health, healthcare financing, and delivery 
systems in the word and, especially in developing countries. Mounting evidence obtained in 
in vitro and in vivo studies, suggests that various traditionally used plants in Asia, India, and Europe 
significantly affect key metabolic alterations culminating in AD-typical neurodegeneration. The 
present article aims to bring the reader up-to-date on the most recent studies and advances 
describing the direct and indirect activities of traditional used plants and its constituents possibly 
relieving features of AD. A variety of traditional used plants and its extracts exerted activities on 
AD related drug targets including AChE activity, antioxidative activity, modulation of Aβ-producing 
secretase activities, Aβ-degradation, heavy metal chelating, induction of neurotrophic factors, 
and cell death mechanisms. Although pre-clinical investigations identified promising drug 
candidates for AD, clinical evidences are still pending.
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 estimates of dementia prevalence across regions. The estimated 
global dementia prevalence in people aged over 60 is approximate 
3.9% with regional prevalence being 1.6% in Africa, 3.9% in Eastern 
Europe, 4.0% in China, 4.6% in Latin America, 5.4% in Western 
Europe, and 6.4% in North America (Qiu et al., 2009). The global 
annual incidence of dementia is estimated to be around 7.5 per 
1000 population (Ferri et al., 2005), with no substantial variations 
across continents except Africa, where incidence rates are reported 
to be lower than in other regions. The incidence rate of dementia 
increases exponentially with age and incidence rates across regions 
of dementia are quite similar (Qiu et al., 2007, 2009). The risk of 
AD grows exponentially with age, doubling approximately every 
5–6 years (Ziegler-Graham et al., 2008). The largest increase in 
absolute numbers of old persons will occur in developing countries; 
it almost triples from 249 mio in 2000 to an estimated 690 mio in 
2030. The developing regions’ share of the worldwide aging popula-
tion will increase from 59 to 71% (Qiu et al., 2007). Most people 
with dementia live in developing countries (60% in 2001). Rates of 
increase are not uniform; numbers in developed countries are esti-
mated to double between 2001 and 2040, but by more than 300% in 
India, China, and their south Asian and western Pacific neighbors 
(Ferri et al., 2005). Hence, the global trend in the phenomenon 
of population aging has dramatic consequences for public health, 
healthcare financing, and delivery systems in the word and, espe-
cially in developing countries (Qiu et al., 2007).
TreaTmenT of alzheimer’s disease – from medical 
chemisTry To planTs
The current standard of care for mild to moderate AD includes 
treatment with acetylcholine esterase inhibitors, such as donepe-
zil or rivastigmine, to improve cognitive function. The NMDA 
inTroducTion
Alzheimer’s disease (AD) is a neurodegenerative disorder character-
ized clinically by progressive memory deficits, impaired cognitive 
function, and altered and inappropriate behavior (Mattson, 2004). 
AD represents the most common form of dementia, which places a 
considerable and increasing burden on patients, caregivers, and soci-
ety. Aging represents the most important risk factor and dementia 
has become one of the major challenges in our societies due to the 
universal phenomenon of population aging in the world (Qiu et al., 
2007). Brain regions involved in learning and memory processes, 
including the temporal and frontal lobes as well as the hippocampus, 
are reduced in size in AD patients as the result of degeneration of 
synapses and death of neurons (Arendt, 2009). AD is considered as 
a protein aggregation disorder, based on two key neuropathologi-
cal hallmarks, namely the hyperphosphorylation of the tau protein 
resulting in the formation of neurofibrillary tangles (NFTs), and 
the increased formation and aggregation of amyloid-beta peptide 
(Aβ) derived from amyloid precursor protein (APP) (Haass and 
Selkoe, 2007). Although the exact underlying cause initiating the 
onset of AD is still unclear, an imbalance in oxidative and nitrosative 
stress, intimately linked to mitochondrial dysfunction, characterizes 
already early stages of AD pathology (Müller et al., 2010).
alzheimer – a worldwide problem wiTh special 
impacT for developing counTries
To understand neurodegenerative diseases is one of the major chal-
lenges of the twenty-first century. The United Nations estimate 
that the number of people suffering from age-related neurode-
generation, particularly from AD, will exponentially increase from 
25.5 million in 2000 to an estimated 114 million in 2050 (Wimo 
et al., 2003). Several meta-analysis have resulted in roughly similar 
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transgenic mice benefited from repeated EGb 761 oral intake, evi-
dent by improved spatial memory, although soluble and Aβ plaque 
burden was unaffected (Stackman et al., 2003). Paradoxically, pro-
tein oxidation increased in Ginkgo-treated animals (Stackman et al., 
2003). The authors speculated that metabolic alterations, mediated 
by vasodilatory and tropic effects of EGb 761, might be responsible 
for this finding.
New promising targets for better understanding the molecular 
mode of EGb 761 action arises from microarray studies. Ginkgo 
supplementation (300 mg/kg diet) induced differential changes in 
mRNA expression in mouse hippocampus and cortex. Noteworthy, 
in the cortex, mRNA for neuronal tyrosine/threonine phosphatase 1 
and microtubule-associated Tau were significantly enhanced. Both 
proteins are associated with the formation as well as breakdown of 
toxic, AD-typical NFTs (Watanabe et al., 2001).
Recently, the safety and effectiveness of a traditional Ginkgo 
fresh extract was tested clinically (Baurle et al., 2009). The tested 
patients suffered from age-related mild cognitive impairment of 
the non-Alzheimer type. About half of all patients experienced an 
improvement in their memory and their ability to concentrate, 
as well as a decrease in symptoms of forgetfulness. The holistic 
fresh Ginkgo extract was found to be safe and, at least, adjuvant 
treatment option for patients with mild cognitive impairments 
(Baurle et al., 2009).
In a nutshell, many placebo-controlled clinical trials proved 
G. biloba to be a useful herbal remedy for attenuating symptoms 
in dementia, with efficiency comparable to those of standard drugs 
in AD treatment (Le Bars, 2003). This notion has been confirmed 
in a recent 3-month study in comparison to donepezil (Mazza 
et al., 2006). Furthermore, EGb 761 has been suggested to pre-
vent neurodegenerative pathologies (Christen, 2004). The ongoing 
GuidAge study, a double-blind randomized trial, will shed fur-
ther light on the efficiency of EGb 761 in the prevention of AD 
(Andrieu et al., 2008).
galanTamine – from folk To modern medicine
Galantamine is an alkaloid known form several members of the 
Amaryllis family (Amaryllidaceae), and the idea for developing a 
medical product for AD from these species seems to be based on 
the local use of one of these species in a remote part of Europe. It 
has become an important therapeutic options used to slow down 
the process of neurological degeneration in AD. Its development 
from little known observational studies in the Caucasus Mountains 
(Southern Russia), to the use of this drug in Eastern European 
countries (esp. Bulgaria) in the treatment of poliomyelitis and 
ultimately to the recent introduction onto Western markets in the 
treatment of AD (Heinrich, 2010). Galantamine was first isolated 
from snowdrop (Galanthus spp.) but today it is obtained from 
Narcissus spp. and Leucojum spp. as well as synthetically (Heinrich 
and Lee Teoh, 2004). According to unconfirmed reports, in the 
1950s, a Bulgarian pharmacologist noticed the use of the common 
snowdrop growing in the wild by people who were rubbing it on 
their foreheads to ease nerve pain. Also, some of the earlier publi-
cations indicate the extensive use of snowdrop in Eastern Europe, 
such as Romania, Ukraine, the Balkan Peninsula, and in the Eastern 
Mediterranean countries. However, Mashkovsky and Kruglikova-
Lvov (1951) published the first work that establishes the acetyl-
(N-methyl-d-aspartate) antagonist memantine has also been 
shown to improve cognitive function in patients with moderate 
to severe AD (Citron, 2010). Nimodipine, an l-type calcium cur-
rent blocker or piracetam, a nootropicum, almost complete the list 
of non-alternative drugs to treat AD (Tsolaki et al., 2001; Evans 
et al., 2004). In addition, common non-cognitive neuropsychiatric 
symptoms, such as mood disorder, agitation, and psychosis often 
require the introduction of medication, even tough no existing 
drug is specifically indicated for their management. However, there 
is no approved treatment with a proven disease-modifying effect 
(Citron, 2010) and interventions with current drugs, if started early 
enough, may at best slow down the fatal pathophysiological altera-
tions leading to manifestation of clinical AD symptoms, but are 
unable reverse the neurodegenerative process.
Beside synthetic drugs, a variety of AD related medicine origi-
nates from traditionally used plants. In this respect, Ginkgo biloba 
and galantamine represent the most famous cases.
GinkGo biloba – from TradiTional chinese medicine 
To a sTandardized drug
Originally, Ginkgo biloba (Coniferae) has been traditionally used 
for respiratory disorders in China and to improve memory loss 
associated with blood circulation abnormalities in Iran (Howes 
et al., 2003). This herb has been subjected to numerous investiga-
tions regarding its potential in cognitive disorders. Standardized 
extracts, particularly EGb 761, derived from the plants’ leaves are 
successfully used as herbal drug for the improvement of cognitive 
and memory impairment (for review see Kumar, 2006). EGb 761 
represents a prototype of plant extracts for attenuating CNS dis-
orders, due to the fact that both flavonoids and terpenic lactones, 
which are partly also present in numerous other plant extracts, 
have been identified as the active principles in Ginkgo extracts as 
well as the ample experimental evidence on EGb 761’s protective 
efficiency in vitro and in vivo. The potential of EGb 761 to attenu-
ate the cytotoxic effects of Alzheimer’s related neurotoxic amyloid 
peptides when added to the culture medium was demonstrated not 
only in neuronal-like cell lines but also primary neurons, though 
with different efficiency (Bastianetto et al., 2000; Yao et al., 2001; 
Eckert et al., 2005). The impact of Ginkgo extract has been largely 
attributed to its antioxidant activity (Yao et al., 2001). The effects 
of oxidative stress were reduced in lymphocytes and brain cells 
derived of EGb 761-treated AD-transgenic and non-transgenic 
mice (Schindowski et al., 2001; Abdel-Kader et al., 2007). Recent 
data, however, indicate that EGb 761 also affects the production 
of neurotoxic beta-amyloid peptides (Aβ), for example, by up-
regulating α-secretase activity both in cells and animals (Abdel-
Kader et al., 2007).
In aged and/or AD transgenic mice, EGb 761 treatment resulted 
in improved memory compared to control animals (Stoll et al., 
1996; Tang et al., 2002). The mechanisms responsible for latter 
observation are still a matter of debate. Whereas Luo et al. (2003) 
reported changes in APP load in rats treated with Ginkgo extract 
(100 mg/kg b.w.) for 15 days, Garcia-Alloza et al. (2006) suggested 
changes in the extent of oxidative stress to account for the neuro-
protection in EGb 761-fed AD mice. Interestingly, the EGb 761-
associated reduction in Aβ plaque-linked oxidative stress in mice 
brain was unaffected by plaque size or number. Similarly, Tg2576 
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available either in whole or sliced dried form. However, usually 
ginseng is used at subclinical doses for a short period and as such, 
it does not produce measurable medicinal effects (Jia et al., 2009). 
Panax notoginseng is widely used in traditional Chinese medicine 
(TCM) to improve learning and memory (Wang and Du, 2009). 
Moreover, protective actions against cerebral ischemia, beneficial 
effects on the cardiovascular system, and haemostatic, antioxidant, 
hypolipidemic, hepatoprotective, renoprotective, and estrogen-like 
activities have been described (Ng, 2006).
Ginsenoside Rg1, a major active component of sanchi ginseng 
(P. notoginseng), was shown to inhibit β-secretase activity in vitro, 
to protect PC12 cells against Aβ
25–35
 (Wang and Du, 2009), and to 
exert neuroprotective effects (Jia et al., 2009). It has to be noted 
that Wang and Du (2009) treated neuronal-like cells with excessive 
Aβ concentrations of 50 μM for 48 h.
Ginsenoside Rg3, one of the major active components of 
sanchi ginseng significantly reduced the levels of Aβ
1–40
 and Aβ
1–42
 
in SK–N–SH cells transfected with Swedish mutant beta-APP. 
Enhanced Aβ degradation is due to Ginsenoside Rg3-induced 
neprilysin expression (Yang et al., 2009), which represents the rate-
limiting enzyme in Aβ degradation (Iwata et al., 2000).
Akebia saponin B was found to antagonize Aβ
25–25
 toxicity in 
PC12 cells (Zhou et al., 2009). Akebia saponin B belongs to the 
saponin fraction of a water extract from Dipsacus Asper Wall. This 
plant is a well-known TCM for enhancing kidney activity and the 
rational to test this pant for AD originates form the idea that accord-
ing to TCM, the etiopathogenesis of AD lies in kidney deficiency 
during aging (Zhou et al., 2009).
Penta-O-galloyl-beta-d-glucopyranose (PGG), a major compo-
nent of the traditional herb Paenoia suffruticosa Andrews (Moutan 
Cortex), inhibits Aβ fibril formation and destabilizes preformed Aβ 
fibrils in a concentration dependent matter (Fujiwara et al., 2009). 
Moreover, the herb improved long-term memory impairment in 
an AD mouse model and inhibited Aβ accumulation in brains 
of treated mice (Fujiwara et al., 2009). The traditional Chinese 
herb Moutan Cortex is commonly used to treat inflammatory 
and pyretic disorders (Hsieh et al., 2006) and possess potent anti-
oxidant, antimutagenic, and antiproliferative effects (Choi et al., 
2002). It was earlier reported that PGG could protect neuronal 
cells from oxidative stress by induction of HO-1 gene expression 
(Choi et al., 2002).
Tenuifolin, a crude extract derived from Polygala tenufolia Willd 
(Polygalaceae) (PTW) was found to decrease Aβ secretion from 
transfected cells, probably due to inhibition of the beta-site APP 
cleaving enzyme (Lv et al., 2009). Treatment of rat cortical neurons 
with PTW enhanced axonal length dose-dependently after Aβ
25–35
-
induced axonal atrophy. However, dendritic atrophy and synaptic 
loss induced by Aβ
25–35
 were not recovered after treatment with 
PTW extract. In contrast, Aβ
25–35
-induced cell damage was com-
pletely inhibited by PTW extract (Naito and Tohda, 2006). PTW 
is classically mentioned as an anti-dementia drug in Chinese and 
Japanese traditional medicine (Naito and Tohda, 2006). It has been 
shown that PFW can improve hippocampus-dependent learning 
and memory, possibly through improvement of synaptic trans-
mission, activation of the MAP kinase cascade, and enhancement 
BDNF levels (Xue et al., 2009). Accordingly, PTW up-regulated 
the expression of BDNF and TrkB mRNA to promote the recovery 
choline esterase inhibiting properties of galantamine isolated from 
Galanthus woronowii. Poliomyelitis was one of the first indications 
for galantamine, especially in the Eastern and Central European, 
since the compound enhances nerve impulse transmission at the 
synapse. Studies indicating blood–brain barrier penetration of 
the alkaloid pioneer the development of CNS-related indications. 
Based on the knowledge of galantamine in both the peripheral and 
central nervous system, many countries in Eastern Europe used it 
as an acknowledged treatment in Myasthenia gravis and muscular 
dystrophy, residual poliomyelitis paralysis symptoms, trigeminal 
neurologica, and other forms of neuritis. A crucial step for the 
success of galantamine as a medicine against AD was based on 
the synthesis developed in the mid-1990s. The scientific rationale 
for using cholinesterase inhibitors in the management of AD is 
based on the cholinergic hypothesis. Impairment of the central 
cholinergic system represents one hallmark of AD, which is char-
acterized by loss of cholinergic neurons in the forebrain and a 
marked decrease in the activity of choline acetyltransferase. Overall, 
galantamine represents an example for the successful ethnobotany-
driven development of a natural product into a clinically important 
drug (Heinrich, 2010).
In the last years, focus on AD drug discovery is shifting away 
from AChE inhibitors and a large number of other targets are cur-
rently being explored.
However, mounting evidence obtained in vitro and in vivo, 
suggests that various traditionally used plants significantly affect 
key metabolic alterations culminating in AD-typical neurodegen-
eration. While the impact of the aforementioned traditional used 
plants on AD has been reviewed comprehensively (Howes et al., 
2003; Houghton and Howes, 2005; Akhondzadeh and Abbasi, 2006; 
Yan et al., 2007), the purpose of the present article is to bring the 
reader up-to-date on the most recent studies and advances describ-
ing the direct and indirect activities of plant constituents possibly 
relieving features of AD. Recently tested AD related drug targets 
include AChE activity (Oh et al., 2004; Joshi and Parle, 2006; Ren 
et al., 2006; Lin et al., 2008; Vasudevan and Parle, 2009), antioxida-
tive activity (Pendry et al., 2005; Lee et al., 2007; Dhanasekaran et al., 
2009), modulation of Aβ-producing secretase activities (Fujiwara 
et al., 2006, 2009; Dhanasekaran et al., 2009; Lv et al., 2009; Wang 
and Du, 2009; Zhou et al., 2009), Aβ-degradation (Lee et al., 2007; 
Yang et al., 2009), heavy metal chelating (Ren et al., 2006), neuro-
trophic factors (Yabe et al., 2003), and cell death mechanisms (Yu 
et al., 2005; Table 1).
The majority of recent reports on plants with traditional uses 
and activities relevant for AD originate from the traditional Chinese 
and Oriental Medicine, as well as from Kampo Ayurveda and 
Mediterranean traditional knowledge.
planTs from TradiTional asian medicine
Ginseng products are popularly referred to as “adaptogen,” which 
connotes that these products purportedly increase to physical, 
chemical, and biological stress and builds up general vitality, includ-
ing physical and mental capacity for work. Panax ginseng roots are 
traditionally taken orally as adaptogens, aphrodisiacs, nourishing 
stimulants, and in the treatment of sexual dysfunction in men. The 
fresh root, can be directly chewed, or soaked in various wines for a 
period of time before drinking or chewing. Ginseng is most often 
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Table 1 | Summary of Plants and its constitutes with traditional use tested recently in vitro, in vivo and in clinical trails for Alzheimer’s disease (AD).
Plant name Active ingredient Traditional use AD drug target References
Panax notoginseng Ginsenoside Rg1 TCM; improve learning and 
memory function
Secretase activity Wang and Du (2009)
P. notoginseng Ginsenoside TCM; improve learning and 
memory function
Neprilysin Yang et al. (2009)
Ginkgo biloba Fresh plant extract TCM; for respiratory disorders, 
improve memory loss
DemTec cognition score Baurle et al. (2009)
Dipsacus asper  Wall Akebia saponin D TCM; enhancing kidney 
function
Aβ toxicity Zhou et al. (2009)
Paeonia suffruticosa 
Andrews
1,2,3,4,6-penta-O-galloyl-
eta-d-glucopyranose
TCM; to treat inflammatory 
and pyretic disorders
Aβ fibril formation, 
stabilization; in vivo long-term 
memory impairment
Fujiwara et al. (2009)
Polygala tenuifolia Willd Tenuifolin (extract) TCM; to improve memory loss Secretase activity; 
morphological plasticity
Lv et al. (2009), Naito 
and Tohda (2006)
Radix salviae miltiorrhizae 
(Dashen)
Triterpenoids; Tanshinone TCM; to treat heard conditions 
and stroke
AChE activity; Aβ toxicity 
in vivo and in vitro; NOS
Lin et al. (2008), Yin 
et al. (2008), Liu et al. 
(2010b)
Danggui-Shaoyao-San Extract TCM, TJM, enhancement of 
women`s health
Apoptosis in vitro Qian et al. (2008), Hu 
et al. (2010)
Toki-shakuyaku-san JD-30 Learning and memory 
Fungi Monascus 
purpureus
Monascus fermented red 
rice
TCM; enhancement of blood 
flow
Ach E activity, antioxidant; 
secretase activity
Lee et al. (2007, 2010)
Uncaria rhynchophylla Triterpene esters and 
uncarinic acids
TCM, oriental medicine; 
improvement of cardiovascular 
and nervous system
Aβ aggregation and fibril 
stabilization
Fujiwara et al. (2006)
Kami-kihi-to Composition of 12 crude 
drug herbs
Kampo; to treat neurosis, 
amnesia, anemia
Aβ toxicity in vivo: neuritic, 
synaptic and myelin losses
Tohda et al. (2008)
Yokukansan Composition of four crude 
drug herbs
Kampo; to treat restless leg 
syndrome and agitation in 
children
Aβ toxicity in vivo: decrease 
in the anxiety, increase in 
locomotor activity in Tg2576 
AD mice
Tabuchi et al. (2009), 
Sekiguchi et al. 
(2009)
Zokumei-to Composition of different 
crude drug herbs
Kampo; to treat postapoplectic 
sequelae
Aβ toxicity in vivo; increase in 
synaptophysin levels, 
abolishes neuronal loss
Tohda et al. (2003)
Bacopa monnieri Bogenines, Steroids, 
Triterpene
Ayurvedic medicine, improve 
intelligence and memory
Ameliorates ACh deficits 
in vivo
Uabundit et al. (2010)
Salvia officinalis Essential oils, containing 
cineole, thujone and others 
Mediterranean, anti-
inflammatory agent
Clinical trial Akhondzadeh et al. 
(2003b)
Crocus sativus Carotenoids and others Mediterranean, Asia; to treat 
treatment for all varieties of 
gastrointestinal ailments
Clinical trial Akhondzadeh et al. 
(2010)
Melissa officinalis Terpenes, tannins, Eugenol, 
Rosmarinic acid
Mediterranean, used as 
anxiolytic or mild sedative 
agent
Clinical trial; AChE inhibition 
in vitro
Akhondzadeh et al. 
(2003a), Dastmalchi 
et al. (2009)
Murraya koenigii Carbazole alkaloids, 
Scoponin
Indian flavor Antiamnestic, reduced 
cholinesterase activity 
Vasudevan and Parle 
(2009)
Cassia obtisufolia Obtusifolin Eastern medicine, used as a 
topical analgesic and 
anti-inflammatory natural 
medicine.
AChE inhibition Kim et al. (2009), 
Drever et al. (2008)
Mitochondrial protection
Calcium stabilization
(Continued)
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Centella asiatica Triterpen glycosides, 
saponies
Ayurveda, anxiolytic agent and 
cerebral tonic
Reducing Aβ in vivo Dhanasekaran et al. 
(2009)
Fungus Ganoderma 
lucidum
Ganoderic acid (Triterpen 
glycoside)
TCM, as anti-tumor, 
immunomodulatory and 
immunotherapeutic agent
Preserving synaptic density; 
preserving Aβ-induced 
apoptosis
Lai et al. (2008)
Desmodium gangeticum Aminoglucosyl-glycerolipids, 
cerebrosides
Ayurveda, treatment of 
neurological disorders
Reserved amnesia, AChE 
inhibition
Joshi and Parle 
(2006)
Lycium barbarum Polysaccharides TCM; used as anti-tumor, 
immunomodulatory, 
anti-hypertension agent
Reverses Aβ and 
homocyteine induced 
apoptosis 
Yu et al. (2005), Ho 
et al. (2010)
Table 1 | Continued
Plant name Active ingredient Traditional use AD drug target References
of the neurons from chronic stress-induced damages (Sun et al., 
2009). The methanol fraction of an ethanolic extract from PTW 
showed antagonistic action on neurotoxicity induced by glutamate 
and serum deficiency in PC12 cells (Li et al., 2008a). Some of the 
active ingredients of PTW are oligosaccharide esters, which provide 
a high in vivo antioxidant activity in senescence-accelerated mice 
(Liu et al., 2010a).
Recently, Lin et al. (2008) have tested the anti-acetylcholineste-
rase activities of aqueous and ethanolic extracts of various TCM. 
Ethanolic extracts from Caulis spatholobi, Radix paeoniae alba, 
and Radix salvia miltiorrhizae were found to have the strongest 
AChE inhibitory activity as indicated by IC
50
 values lower than 
10 μg/ml extract. The most active extract from Radix salviae milti-
orrhizae was further fractionated and found that AChE inhibi-
tion is due to the presence of two triterpenoids (Lin et al., 2008) 
confirming earlier data (Ren et al., 2004). Yin et al. (2008) tested 
the effect of phenanthrofurane quinone derivatives of salviae 
miltiorrhizae triterpenoids known as tanshinones on the lev-
els of nitric oxide synthase and AChE in brains of an AD rat 
model. In TCM radix salviae miltiorrhizae (Danshen) is used to 
prevent and treat heart conditions and strokes (Li et al., 2008b). 
Tanshinone modulates AChE and NOS protein concentrations in 
the hippocampus of cranial Aβ
1–42
 injected rats (Yin et al., 2008). 
Recently, the neuroprotective effects of tanshinone was demon-
strated in cortical neurons (Liu et al., 2010b). Pretreatment of 
the cells with Tanshinone prior to Aβ
25–35
 exposure suppressed 
Aβ-induced cellular events, such as loss in viability, apoptosis, 
decrease in superoxide dismutase, and glutathion peroxidase 
activity, increased ROS and decreased mitochondrial membrane 
potential (Liu et al., 2010b).
Danggui-Shaoyao-San (DSS; Tangkuei or Peony Powder) (Toki-
Shakuyaku-San, TSS in Japanese), used as TCM and TJM for centu-
ries for the enhancement of women’s health, e.g., for gynecological 
and obstetrical purposes (Qian et al., 2008). In early studies it was 
shown that a powdered extract of DSS ameliorates dysfunction of 
the central cholinergic nervous system and scopolamine-induced 
decrease in ACh levels in mouse brain (Itoh et al., 1996). In another 
study the effects of aqueous extract of Danggui-Shaoyao-San on 
naturally aged mice were examined to investigate the pharmaco-
logical basis for its therapeutic efficacy on senile dementia. In agree-
ment with earlier data (Komatsu et al., 1999) the results showed that 
DSS improves impaired cognitive function of aged mice. Results 
indicated that DSS ameliorates age-related memory dysfunction, 
modulates metabolism of monoamine neurotransmitters, and 
 protects ultra structure of the cortex (Kou et al., 2005). These find-
ings suggest that DSS may be a useful therapeutic agent for senile 
dementia, especially AD (Kou et al., 2005). Accordingly, in a recent 
in vitro study, DSS exhibits anti-apoptotic effects after challenging 
PC12 cells with hydrogen peroxide: the compound counteracts the 
down regulation of anti-apoptotic BCl-2 protein, the upregulation 
of pro-apoptotic Bax protein, the release of mitochondrial cyto-
chrome c, and sequential activation of caspases (Qian et al., 2008). 
Moreover, DSS significantly reduced the Aβ
25–35
-induced neuronal 
death and the lipid peroxidation in vivo (Egashira et al., 2005). 
Accordingly, the DSS extract JD-30 ameliorated Aβ
25–35
 induced 
impairment of spatial learning and memory in mice, as well as 
inhibition of long-term potentiation (LTP) in the hippocampus 
(Hu et al., 2010).
The seeds of Cassia obtisufolia (Fabaceae) have long been used in 
traditional eastern medicine and more recently the ethanolic frac-
tion of the seeds has been shown to attenuate memory in mice (Kim 
et al., 2009). Cassia obtisufolia extract (COE) attenuated calcium 
dysregulation and promoted mitochondrial protection in mouse 
primary hippocampal cultures. However, COE had no effect on 
cell death induced by incubation with oligomeric Aβ (Drever et al., 
2008). Gluco-obtusifolin, isolated from the seeds of C. obtusfolia 
L., and its aglycone, obtusifolin, was found to inhibit acetylcho-
linesterase activity in vitro and ex vivo (Kim et al., 2009). However, a 
recent study reported C. obtusfolia related hepatotoxicity in chronic 
hepatitis B patients (Yuen et al., 2006).
Lycium barbarum (Solanaceae; Wolfberry) is a fruit that is 
known for its eye-protective and anti-aging properties in Asian 
countries (Ho et al., 2010). Recent in vitro investigations evaluated 
that pretreatment of rat cortical neurons with an extract isolated 
from L. barbarum significantly reduced the release of lactate dehy-
drogenase (LDH). In addition, it attenuated Aβ peptide-activated 
caspases-3-like activity by reduced phosphorylation of JNK-1 and 
its substrates c-Jun (Yu et al., 2005). Recently, polysaccharides were 
identified as active ingredient of L. barbarum that provides protec-
tive properties against Aβ and homocysteine (Ho et al., 2010).
Uncaria rhynchophylla (Rubiaceae) has been used as a TCM for 
cardiovascular and neurological diseases (Chou et al., 2009) and 
for convulsive disorders in Oriental medicine (Lee et al., 2003). 
Triterpene esters and uncarinic acids C and D were identified as 
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Only few studies of Zokumei-to used as Kampo in Japanese 
medicine for postapoplectic sequelae have been carried out (Tohda 
et al., 2003). Kamatsu and coworkers generated pre-clinical evi-
dence for Zokumei-to as possible drug for AD (Tamura et al., 2002). 
Treatment of mice intracerobroventricularly injected with Aβ
25–35
 
showed beneficial effects on memory impairment and synaptic loss 
after Zokumei-to treatment (Tohda et al., 2003).
Monascus-fermented red mold rice (RMR), a TCM and health 
food, include monacolins and multifunctional metabolites. RMR is 
traditionally used for improvement of blood circulation (Ma et al., 
2000). Preparation of RMR following ancient methods by ferment-
ing the fungal strain Monascus purpureus Went on moist and sterile 
rice indicated the presence of a group of metabolites belonging to 
the monacolin family of polyketides, together with fatty acids, and 
trace elements. The presence of these compounds may explain in 
part the cholesterol-lowering ability associated with this traditional 
Chinese food (Ma et al., 2000). Monacolins, like statins, affect lipid 
homeostasis by inhibition HMG-CoA reductase the rate-limiting 
enzyme in cholesterol biosynthesis (Wang and Lin, 2007; Barrios-
Gonzalez and Miranda, 2010). Accordingly, oral administration of 
Monascus powder in hyperlipidemic hamsters proved to decrease 
TC, TG, and LDL-C levels (Lee et al., 2006). In vitro studies indi-
cated that ethanolic RMR extract provides stronger neuroprotec-
tion in rescuing cell viability as well as repressing inflammatory 
response and oxidative stress. RMR administration to mice potently 
reverses the memory deficit in the memory task. Moreover, in vivo 
RMR potently reversed Aβ
1–40
 infusion induced acetylcholineste-
rase activity, reactive oxygen species, and lipid peroxidation and 
increases total antioxidant status and superoxide dismutase activity 
in brain. Compared to lovastatin the protective activities of RMR 
was more significant (Lee et al., 2007). A recent study showed that 
RMR provided neuroprotection by reduction of Aβ
1–40
 formation 
and deposition due to suppressing the cholesterol-raised beta-
secretase activity and apolipoprotein E expression. Moreover, RMR 
mediated the proteolytic process of APP toward neuroprotective 
sAPPα secretion in hippocampus (Lee et al., 2010).
planTs from TradiTional orienTal medicine
Bacopa monnieri (Scrophulariaceae) has been used in the tradi-
tional system of Ayurvedic medicine to improve intelligence and 
memory (Uabundit et al., 2010). A randomized, double-blind, pla-
cebo-controlled trial provides further evidence that B. monnieri has 
potential for safely enhancing cognitive performance in the aging 
(Calabrese et al., 2008). Recent in vivo studies identified neuropro-
tective effects in a rat model of AD: escape latency time in Morris 
water maze test was improved and the reduction of neurons was 
mitigated after B. monnieri treatment (Uabundit et al., 2010).
Murraya koenigii (Rutaceae) leaves commonly known as curry 
patta are added routinely to Indian gravy and vegetarian dishes 
as favorite condiment (Vasudevan and Parle, 2009). The leaves 
of M. koenigii are also used as Ayurvedic medicine as antimicro-
bial, anti-inflammatory, hepatoprotective, anti-hypercholestero-
lemic, or anti-inflammatory remedy (Xie et al., 2006; Arulselvan 
and Subramanian 2007; Birari et al., 2010). Diets composed of 
M. koenigii leaves significantly improved memory scores and 
reduced amnesia induced by scopolamine and diazepam in young 
active components of U. rhynchophylla (Shi et al., 2003; Lee et al., 
2008; Umeyama et al., 2010). The alkaloids of U. rhynchophylla 
mainly act on the cardiovascular and central nervous system includ-
ing hypertension, brachycardia, antiarrhythmia, and protection of 
cerebral ischemia and sedation. The active mechanisms were related 
to blocking of calcium channels, opening of potassium channels, 
and regulating of nerve transmitters transport and metabolism 
(Shi et al., 2003) as well as suppression of c-Jun N-terminal kinase 
(JNK) phosphorylation (Hsieh et al., 2009). U. rhynchophylla 
significantly inhibited NMDA receptor-activated ion currents in 
acutely dissociated hippocampal CA1 neurons in cultured brain 
slices (Lee et al., 2003). Moreover, anxiolytic effects of the aqueous 
extract of U. rhynchophylla were reported (Jung et al., 2006). In 
view to AD, U. rhynchophylla intensively inhibited Aβ aggregation 
and significantly destabilized preformed Aβ
1–40
 and Aβ
1–42
 fibrils 
(Fujiwara et al., 2006).
Kami-kihi-to a TCM (Jia-Wei-Gui-Pi-Tang), which is composed 
of 12 crude herbs also used in Japanese kampo tradition. It has 
been used to treat neurosis, amnesia, anemia, and some other 
diseases (Nishizawa et al., 1994). Kampo uses fixed combinations 
of herbs in standardized proportions according to the classical 
literature of Chinese medicine. Today in Japan, Kampo is inte-
grated into the Japanese health care system (Dharmananda, 2004). 
Clinically, Kihi-to may improve chronic immune thrombocyto-
penic purpura (Yamaguchi et al., 1993). However, possible adverse 
effects on glycemia were reported (Kawasaki et al., 2000). Recently, 
effects of Kihi-to on memory deficits and losses of neuritis and 
synapses were examined using AD mice. Short time administration 
of Kihi-to resulted in marked improvements of Aβ
25–35
 induced 
impairments in memory in mice. Kihi-to was shown to attenuate 
neuritic, synaptic, and myelin losses in brain of cranial Aβ injected 
mice (Tohda et al., 2008). An aqueous extract of Ganoderma luci-
dum (Ganodermataceae; Lingzhi mushroom; GLE), a medicinal 
fungus used clinically in many Asian countries to promote health 
and longevity was also shown to attenuate Aβ-induced synapto-
toxcitiy by preserving the synaptic density protein, synaptophysin 
(Lai et al., 2008). In addition, GLE antagonized Aβ-triggered pro-
apoptotic caspase cleavage and attenuated c-JNK phosphorylation 
(Lai et al., 2008).
Yokukansan (Yi-ga-san), a remedy composed of four herbs, tra-
ditionally used for restlessness and agitation in children (Tsuyoshi 
and Jun, 2009), has in recent times attracted attention as drug to 
treat dementia including AD (Maruyama et al., 2006; de Caires and 
Steenkamp, 2010). The results of a recent pilot study indicated that 
Yokukansan can alleviate the behavioral symptoms of frontotempo-
ral dementia (Kimura et al., 2010). An open-label study suggested 
that Yokukansan might be effective in the treatment of behavioral 
and psychological symptoms of dementia (Hayashi et al., 2010). 
Evidences for a possible mode of action comes from two recent 
preclinical studies: Yokukansan reduces aggressiveness without sup-
pressing physical activity in mice injected intracerebroventricular 
with Aβ
25–35
 (Sekiguchi et al., 2009). Using an AD mouse model 
Tabuchi et al. (2009) demonstrated that Yokukansan ameliorates 
learning deficits and non-cognitive defects including a decrease 
in the anxiety and an increase in locomotor activity observed in 
Tg2576 mice.
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